Eli Lilly Commits $4.5B To New Facility, Banking On Mounjaro, Zepbound's Weight Loss Success Despite Short-Term Stock Challenges
"Cash is king" is outdated, these assets are more worth buying.
The outlook for cash assets is becoming bleak, and a rate cut by the Federal Reserve will erode the yield of cash assets.
Bristol-Myers Tops Growth Chart Among S&P 500 Healthcare Stocks in Q3
Novo Nordisk Is Still a Buy, Analysts Say. Slowing Growth for Ozempic and Wegovy Isn't a Problem. -- Barrons.com
Eli Lilly (NYSE:LLY) Eyes Broader Market for Weight-Loss Drugs
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030